Researchers hope to extend the genomics revolution from a catalog of genes to a catalog of the three-dimensional shapes of the proteins for which the genes code. This untold wealth of biochemical information at the atomic level is providing drug designers with both new targets for drugs and hints for making them successful. But some researchers worry that the nascent field will spawn a high-stakes race between publicly funded academic researchers and private companies, similar to the competition over the human genome project.